|
Balance Sheet Cash Flow Statement 400 Berwyn Park, 899 Cassatt Rd., Ste. 115 Berwyn, PA 19312 PA Tel. 610-989-4208 |
Type: Public
On the web:
http://www.encorium.com
Employees:
235
Employee growth: (14.5%)
Encorium Group (formerly Covalent) is loosening some research client ties. The contract research organization (CRO) manages all stages of clinical trials for pharmaceutical, biotech, and medical device firms worldwide using both full-time and contract personnel. It provides program design, trial and data management, biostatistical analysis, medical and regulatory services, and quality assurance. The company also provides technology solutions, including interactive speech recognition systems and Internet data systems. In response to financial difficulties, Encorium is restructuring and selling off its two core subsidiaries. It has divested its US operations and plans to sell its Finland-based subsidiary.
Key numbers for fiscal year ending December, 2008:
Sales: $35.9M
One year growth: (2.4%)
Net income: ($21.1)M
Officers:
Chairman: Kai E. Lindevall
Interim CFO: Philip L. (Phil) Calamia
VP Business Development: Michael Brown
Competitors:
Covance
Pharmaceutical Product Development
Quintiles Transnational
